Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
66 participants
INTERVENTIONAL
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding
NCT02849691
Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes
NCT00431977
Anti-thrombotic and Glucose Lowering Therapy in Diabetic Patients Undergoing PCI
NCT04481997
Changes of Serum Orphanin FQ in Patients With Coronary Heart Disease in Different Courses of Diabetes Mellitus
NCT04572802
Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes
NCT00431717
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DPP-4 Inhibitor
Any dose of Sitagliptin for 6 months with any other oral anti-diabetic medication
Sitagliptin
Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
Non DPP-4 Inhibitor
Oral anti-diabetic medication except DPP-4 inhibitor
Non DPP-4 Inhibitor
This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sitagliptin
Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
Non DPP-4 Inhibitor
This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known hypersensitivity or contraindication to any of the following medications: Heparin, aspirin, clopidogrel, sirolimus, siptagliptin and statin
* Congestive heart failure (patients with LVEF \<30% or cardiogenic shock)
* Uncontrolled myocardial ischemia (repeated chest pain or dyspnea after revascularization)
* Uncontrolled ventricular arrhythmia
* History of malignancy with chemotherapy
* Serious hematologic disease (e.g. CML, MDS)
* Current infectious disease needs antibiotics therapy
* Creatinine level \>1.5 mg/dL or dependence on dialysis
* Other severe concurrent illness (e.g. active infection, malignancy).
* Life expectancy of less than one year
* Pregnancy or women with potential childbearing
* Type I DM
* Treatment with insulin
* History of pancreatitis
* Who cannot read the informed consent form (e.g. illiteracy, foreigner)
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chung-Ang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sang-Wook Kim
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sang-Wook Kim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Keimyung University Hospital
Daegu, , South Korea
Chonnam National University Hospital
Gwangju, , South Korea
Jeju National University Hospital
Jeju City, , South Korea
Chung-Ang University Hospital
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Ajou University Hospital
Suwon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAU001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.